Xtant Medical and Dilon Technologies Announce Exclusive U.S. Distribution Agreement for Dilon's HEMOBLAST® Bellows Product Xtant Medical (NYSE:XTNT) acquired exclusive U.S. distribution rights to Dilon Technologies' HEMOBLAST® Bellows, a pre-loaded hemostatic powder for minimal to moderate surgical bleeding. Xtant will integrate Dilon's approximately 20-person U.S. sales team and aims to expand penetration of an estimated $2.0 billion global hemostatic market.HEMOBLAST contains collagen, human thrombin, and bovine chondroitin sulfate and requires no prep. Xtant plans to update its full-year 2026 financial guidance when reporting Q1 2026 results.

#XTNT Xtant Medical and Dilon Technologies Announce Exclusive U.S. Distribution Agreement for Dilon's HEMOBLAST® Bellows Product

www.stocktitan.net/news/XTNT/xtant-medical-...

Montana plans donor memorial as 86% of residents register Planned for Montana's Capitol grounds in Helena, the memorial is privately funded and targets Summer 2028 completion as donor awareness efforts continue.

#XTNT Xtant Medical and Montana Governor's Office of Community Service Announce Support for "Threshold of Life" Memorial

www.stocktitan.net/news/XTNT/xtant-medical-...

After a $21.4M asset sale, Xtant ended 2025 with $17.3M cash Gross margin reached 62.9% and operating cash flow hit $12.5M, strengthening liquidity. Xtant later collected another $10.5M and sees 2026 revenue at $95M-$99M.

#XTNT Xtant Medical Reports Fourth Quarter and Full-Year 2025 Financial Results

www.stocktitan.net/news/XTNT/xtant-medical-...

Xtant Medical sets March 31 call for Q4 and full-year 2025 results Results arrive before the market opens March 31, followed by an 8:30 a.m. ET call with the CEO and CFO. A webcast replay will be posted online.

#XTNT Xtant Medical to Announce Fourth Quarter and Full Year 2025 Financial Results on March 31, 2026

www.stocktitan.net/news/XTNT/xtant-medical-...

Spine asset sale brings Xtant $21.4M to cut debt, add cash Extra $10.7M payment from Companion Spine lifts total proceeds for Coflex and Paradigm OUS sale to $21.4M, letting Xtant trim debt and add liquidity.

#XTNT Xtant Medical Finalizes Companion Spine Transactions

www.stocktitan.net/news/XTNT/xtant-medical-...

Xtant Medical Reports Third Quarter 2025 Financial Results Xtant Medical (NYSE:XTNT) reported Q3 2025 revenue of $33.3M, up 19% YoY, with gross margin 66.1% versus 58.4% a year earlier. The company delivered net income $1.3M and adjusted EBITDA $4.5M, and generated $4.6M cash from operations. Cash and equivalents were $10.6M at 9/30/2025. Xtant reiterated full‑year 2025 revenue guidance of $131M–$135M (approx. 11%–15% growth over 2024).Recent items: pending sale of certain hardware assets and all OUS businesses to Companion Spine expected to close by year‑end, and launch of CollagenX bovine collagen particulate for surgical wound closure. Webcast scheduled 11/11/2025 at 8:30 AM ET.

#XTNT Xtant Medical Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/XTNT/xtant-medical-...

Xtant Medical Reports Strong Q2 2025 Financial Results with Growth in Revenue and Profitability Xtant Medical Holdings, Inc. announces Q2 2025 financial results showing an 18% rise in revenue and a return to net profitability, signaling strong performance and strategic focus.

Xtant Medical Reports Strong Q2 2025 Financial Results with Growth in Revenue and Profitability #United_States #Belgrade #Xtant_Medical #OsteoFactor_Pro #XTNT

Xtant Medical Reports Second Quarter 2025 Financial Results Xtant Medical (NYSE American: XTNT) reported strong Q2 2025 financial results with revenue growing 18% to $35.4 million. The company achieved significant improvements, including a gross margin of 68.6% and net income of $3.6 million, compared to a net loss in the prior year.Key developments include the planned sale of non-core assets to Companion Spine for $19.2 million and the launch of two new products: OsteoFactor Pro™ and Trivium™. The company has raised its FY25 revenue guidance to $131-135 million, projecting 11-15% growth. Operating performance showed marked improvement with Adjusted EBITDA of $6.9 million and positive operating cash flow of $1.2 million.

#XTNT Xtant Medical Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/XTNT/xtant-medical-...

Xtant Medical's $19.2M Strategic Sale Transforms Company into Pure-Play Orthobiologics Leader $19.2M deal includes Coflex/CoFix implants and international operations. Strategic move to focus on high-margin orthobiologics and reduce debt. See full details.

#XTNT Xtant Medical Announces Definitive Agreements for the Sale of its Coflex® and CoFix® Spinal Implants and All OUS Businesses to Companion Spine

www.stocktitan.net/news/XTNT/xtant-medical-...

Xtant Medical Introduces First-Ever Complete Orthobiologic Portfolio with New Bone Growth Technology New OsteoFactor Pro delivers dual-phase growth factors for enhanced bone regeneration. First solution spanning all 5 major orthobiologic categories. Learn more.

#XTNT Xtant Medical Announces the Launch of OsteoFactor Pro™

www.stocktitan.net/news/XTNT/xtant-medical-...

Xtant Medical Reports First Quarter 2025 Financial Results Xtant Medical (NYSE American: XTNT) reported strong Q1 2025 financial results with revenue increasing 18% year-over-year to $32.9 million. The company achieved positive net income of $58,000, compared to a net loss of $4.4 million in Q1 2024. Key highlights include gross margin of 61.5%, Adjusted EBITDA of $3.0 million, and positive operating cash flow of $1.3 million. The growth was primarily driven by increased orthobiologics sales and licensing revenue. Xtant recently launched Trivium™, a next-generation demineralized bone matrix allograft, and completed a secondary private sale of shares by OrbiMed Advisors. Based on strong performance, the company increased its 2025 revenue guidance to $127-131 million, representing 8-12% growth.

#XTNT Xtant Medical Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/XTNT/xtant-medical-...

Xtant Medical Sets Q1 2025 Earnings Date: MedTech Leader to Discuss Surgical Solutions Growth on May 12 CEO Sean Browne to present Q1 2025 results on May 12 at 4:30 PM ET. Join the surgical solutions leader's conference call to analyze latest performance. Get details.

#XTNT Xtant Medical to Issue First Quarter 2025 Financial Results on May 12, 2025

www.stocktitan.net/news/XTNT/xtant-medical-...

Major Shakeup: OrbiMed Sells Entire Xtant Medical Stake as Revenue Surges 19% OrbiMed sells 73.1M shares to new investors as Xtant projects strong Q1 growth. Strategic shift focuses on high-margin products. Full analysis inside.

#XTNT Xtant Medical Announces Secondary Private Sale of Existing Shares by OrbiMed and Preliminary First Quarter 2025 Revenue Growth of 18% to 19%

www.stocktitan.net/news/XTNT/xtant-medical-...

Can Xtant Medical's 28% Revenue Growth Offset Rising Losses? Key Metrics Revealed Strong revenue growth coupled with margin pressure as Xtant implements $5M cost reduction plan. Company projects positive cash flow by late 2025.

#XTNT Xtant Medical Reports Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/XTNT/xtant-medical-...

Breaking News: ( NYSE: #XTNT ) Xtant Medical Expands Product Portfolio with the Launch of the Cortera(R) Posterior Fixation System

#StockMarket #News